Successful Alectinib Treatment for Carcinoma of Unknown Primary with <i>EML4-ALK</i> Fusion Gene: A Case Report

Successful Alectinib Treatment for Carcinoma of Unknown Primary with <i>EML4-ALK</i> Fusion Gene: A Case Report

Gene alteration in anaplastic lymphoma kinase (ALK) is rare, and the efficacy of ALK inhibitors in the treatment of carcinoma of unknown primary (CUP) with <i>ALK</i> alteration remains unclear. The patient was a 56-year-old woman who presented with cervical lymph node swelling. Computed...

Full description

Bibliographic Details
Main Authors: Keiji Sugiyama, Ai Izumika, Akari Iwakoshi, Riko Nishibori, Mariko Sato, Kazuhiro Shiraishi, Hiroyoshi Hattori, Rieko Nishimura, Chiyoe Kitagawa
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Current Oncology
Subjects:
carcinoma of unknown primary
next-generation sequencing
<i>EML4-ALK</i>
alectinib
Online Access:https://www.mdpi.com/1718-7729/28/3/180

Similar Items

Similar Items